Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.38 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549889 | 0.86 | GALR1 (0.45) | PIK3CA | |
| SCHEMBL6233417 | 0.85 | GALR1 (0.38) | — | |
| SCHEMBL6429807 | 0.85 | HTT (0.39) | — | |
| SCHEMBL5553491 | 0.82 | GALR1 (0.46) | PIK3CA | |
| SCHEMBL6427917 | 0.81 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL6233857 | 0.81 | PIK3CA (0.41) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL6430113 | 0.80 | VNN1 (0.33) | PIK3CAMTOR | |
| SCHEMBL6229485 | 0.79 | GALR1 (0.41) | PIK3CA | |
| SCHEMBL6233437 | 0.79 | GALR1 (0.46) | — | |
| SCHEMBL5029329 | 0.79 | GALR1 (0.42) | PIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-06-09 | — | — | US | claimed |
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-10-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209882-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | PIK3CA 2359/4885PIK3R1 1081/4885MTOR 671/4885 |
| US-20050124619-A1 | Medical devices employing triazine compounds and compositions thereof | PTGIS, AREG, TGFB1 | PIK3CA 2731/4885PIK3R1 1175/4885MTOR 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.